StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX - Free Report) in a research report sent to investors on Tuesday. The brokerage issued a hold rating on the stock.
Brooklyn ImmunoTherapeutics Stock Performance
Shares of Brooklyn ImmunoTherapeutics stock traded up $0.08 during trading on Tuesday, hitting $1.10. 19,433 shares of the company's stock were exchanged, compared to its average volume of 515,543. The business has a 50-day simple moving average of $1.36 and a 200-day simple moving average of $1.72. Brooklyn ImmunoTherapeutics has a 52-week low of $0.17 and a 52-week high of $10.10. The stock has a market capitalization of $64.71 million, a price-to-earnings ratio of -0.45 and a beta of 4.61.
Brooklyn ImmunoTherapeutics Company Profile
(
Get Free Report)
Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.
Further Reading
Before you consider Brooklyn ImmunoTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Brooklyn ImmunoTherapeutics wasn't on the list.
While Brooklyn ImmunoTherapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
